Rivastigmine as support in the dilemmma of the treatment of hallucinations occuring in Parkinson's disease;Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinates optredend bij ziekte van Parkinson

Tijdschrift voor Gerontologie en Geriatrie

Volumn 37, Issue 3, 2006, Pages 117-120

  Rovers, J M P ^a   Dautzenberg, P L J ^a   Ter Bruggen, J P ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; RIVASTIGMINE;

ABSENCE OF SIDE EFFECTS; AGITATION; ARTICLE; DOSE RESPONSE; HALLUCINATION; HUMAN; MEMORY; PARKINSON DISEASE;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINATIONS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES; TREATMENT OUTCOME;

EID: 33746871839     PISSN: 01679228     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson's disease? J Neurol 2002;249:419-23.
2. Goetz CG, Stebbings GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.
3. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenollogy and risk factors. Brain 2000;123:733-45.
4. Schrag A. Psychiatric aspects of Parkinson's disease. An update. J Neurol 2004;251:795-804.
5. Laar van T. Achtergrond en behandeling van cognitieve stoomissen en hallucinates bij de ziekte van Parkinson. Tijdschrift voor Neurologie en Neurochirurgie 2006;107:32-9.
6. Lemstra AW, Eikelenboom P, Gool v WA. Cholinerg deficiëntie syndroom als een indicator voor cholinesterase remmers. Ned Tijdschr Geneeskd 2003;147:2201-3.
7. McKeith I, Del Ser T, Spano P-F et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000;356:2031-6.
8. Emre M, Aarsland d, Albanese A et al. Rivastigmine for dementia associated with parkinson's disease. N Eng J Med 2004;351:2509-18.
9. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease. Safety considerations. Drug safety 2003;26(9):643-659.
10. Finkel SF. Pharmacology of antipsychotics in the elderly: a focus on atypicals. J Am Geriatr Soc 2004;52:S258-S265.
11. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series. Current medical research and opinion 2002;18:258-264.
12. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders 2001;16:1171-4.